帕博西利布
细胞周期蛋白依赖激酶
乳腺癌
医学
细胞周期蛋白依赖激酶4
癌症
CDK抑制剂
恶性肿瘤
后天抵抗
内科学
转移性乳腺癌
癌症研究
机制(生物学)
肿瘤科
药理学
细胞周期
细胞周期蛋白依赖激酶2
哲学
认识论
作者
Chawnshang Chang,Ho Yin Pekkle Lam
出处
期刊:Anticancer Research
[Anticancer Research USA Inc.]
日期:2023-11-29
卷期号:43 (12): 5283-5298
被引量:1
标识
DOI:10.21873/anticanres.16732
摘要
Breast cancer (BC) is a common malignancy in women, with hormone receptor (HR)-positive subtype responsible for approximately 70% of cases. Currently, patients with metastatic HR-positive BC rely on endocrine therapy and cyclin-dependent kinase (CDK)-4/6 inhibitors for treatment. Currently, approved CDK4/6 inhibitors include palbociclib, ribociclib, and abemaciclib. However, clinical evidence of CDK-4/6 inhibitor resistance is emerging, suggesting that the gap in the knowledge of its resistance mechanism requires further investigation. This review discusses the mechanisms of CDK4/6 inhibitor resistance in BC, including both intrinsic and extrinsic mechanisms. We also discuss possible alternative strategies to overcome CDK4/6 inhibitor resistance in future clinical applications.
科研通智能强力驱动
Strongly Powered by AbleSci AI